Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445611 inflammatory response after LPS challenge in healthy participants
NL-OMON60490Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of SAR445611, sponsored by Sanofi. Primary endpoint: Primary endpoint(s). Started Jun 2024; status: completed.
02
Drugs
SAR445611
Beyond the preview
Go deeper on NL-OMON60490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60490.